Emcure Pharmaceuticals Limited IPO Detail
Incorporated in 1981, Emcure Pharmaceuticals Limited, an Indian pharmaceutical company, develops, manufactures, and globally markets a wide range of pharmaceutical products across several major therapeutic areas.
The company has been ranked 13th in domestic sales among pharmaceutical companies in India for MAT September 2023 and 4th in market share in its covered markets for the same period. Additionally, it is the leading pharmaceutical company in gynaecology and HIV antiviral therapeutic areas for the MAT September 2023.
In the six months ended September 30, 2023, and the Financial Year 2023, sales in India contributed 50.84% and 53.16% of the company's total revenue, respectively. The company's Domestic sales grew at a CAGR of 10.80% between September 2019 and September 2023, outperforming the Indian pharmaceutical market.
As of September 30, 2023, Emcure Pharma employed 552 scientists and operated five research facilities in India. They filed over 1,800 documents globally, including 204 in the EU and 133 in Canada. They had 201 granted patents, 33 pending patent applications, and submitted 102 drug master files.
Emcure Pharmaceuticals has 13 manufacturing facilities in India. These facilities can produce various pharmaceutical and biopharmaceutical products, including pills, liquids, injectables, and complex ingredients such as chiral molecules, iron molecules, and cytotoxic substances.
As of September 30, 2023, the company's marketing and distribution network in India was supported by over 5,000 field personnel who regularly interacted with healthcare providers. The distribution network included over 5,000 stockists, served by 37 carry-and-forward agents.
Company Promoters
Satish Mehta and Sunil MehtaIPO Details
| IPO Opening Date | Jul 03, 2024 |
| IPO Closing Date | Jul 05, 2024 |
| Issue Type | Book Built Issue IPO |
| Face Value | ₹10 per equity share |
| IPO Price | ₹960 - 1008 per equity share |
| Market Lot | 14 Shares |
| Min Order Quantity | 14 Shares |
| Listing At | BSE, NSE |
| Issue Size | ₹1,952.03 Cr |
| Fresh Issue | ₹800.00 Cr |
| Offer for Sale | ₹1,152.03 Cr |
| Employee Discount | ₹Rs 90 |
| Retail Portion | 35% |
IPO Tentative Timetable
The Emcure Pharmaceuticals Limited IPO open date is Jul 03, 2024, and the close date is Jul 05, 2024. The issue may list on Jul 10, 2024.
| IPO Open Date | Jul 03, 2024 |
| IPO Close Date | Jul 05, 2024 |
| Basis of Allotment Date | Jul 08, 2024 |
| Initiation of Refunds | Jul 09, 2024 |
| Credit of Shares to Demat Account | Jul 09, 2024 |
| IPO Listing Date | Jul 10, 2024 |
IPO Lot Size
The Emcure Pharmaceuticals Limited IPO market lot size is 14 shares. A retail-individual investor can apply for up to 14 lots (196 shares or ₹197568).
| Application | Lots | Shares | Amount (Cut-off) |
|---|---|---|---|
| Minimum | 1 | 14 | ₹14112 |
| Maximum | 14 | 196 | ₹197568 |
IPO Promoter Holding
| Pre Issue Share Holding | 98.90% |
| Post Issue Share Holding |
Company Financials:
For the year/period ended (₹ in Cr.)
| Financial Year | Total Assets | Total Revenue | Profit After Tax |
|---|---|---|---|
| 31-Mar-22 | 6063.47 | 5918.86 | 702.56 |
| 31-Mar-23 | 6672.53 | 6031.72 | 561.85 |
| 31-Mar-24 | 7806.16 | 6715.24 | 527.58 |
Objects of the Issue:
- Repayment and/ or prepayment of all or a portion of certain outstanding borrowings availed by the company; and
- General corporate purposes
Emcure Pharmaceuticals Limited IPO Registrar:
Link Intime India Private Ltd
Emcure Pharmaceuticals Limited IPO Lead Manager(s):
Kotak Mahindra Capital Company Limited Axis Capital Limited J.P. Morgan India Private Limited Jefferies India Private Limited
Company Contact Information:
Emcure Pharmaceuticals Limited
Plot No. P-1 and P-2,
IT-BT Park, Phase II, M.I.D.C.,
Hinjawadi, Pune -411 057
